Bramley T A, Stirling D, Swanston I A, Menzies G S, McNeilly A S, Baird D T
J Endocrinol. 1987 May;113(2):317-27. doi: 10.1677/joe.0.1130317.
Corpora lutea were obtained from 52 women undergoing laparotomy during the luteal phase of the menstrual cycle. In addition, stromal, thecal and granulosa cell preparations were obtained from seven women undergoing ovariectomy during the late follicular-preovulatory phase of the cycle. The specific binding of a 125I-labelled gonadotrophin-releasing hormone (GnRH) agonist [D-Ser(But)6] GnRH(1-9)-ethylamide (buserelin) and of human chorionic gonadotrophin (hCG), human FSH (hFSH), human prolactin (hPRL) and human low-density lipoprotein (hLDL) to tissue homogenates was measured under optimal conditions. Bound LH/hCG was estimated by elution with acid-citrate buffer, followed by radioimmunoassay of released hormone. Binding of GnRH agonist, though variable, was highest in mid-luteal corpus luteum and high binding was also present in three out of four corpora lutea of pregnancy. Binding of LH/hCG increased significantly with luteinization, reaching maximal levels in the mid-luteal phase before falling significantly. Occupancy of LH receptors by bound LH was relatively constant throughout the luteal phase (10.7-35.3%), but occupancy increased to greater than 90% in corpora lutea from early pregnancy. Binding of hFSH was variable, with only five out of 50 corpora lutea having binding greater than 10 pg/micrograms DNA. Similarly, hPRL binding varied markedly with only six out of 44 having binding greater than 50 pg/micrograms DNA. Binding of LDL was highest in the early- to mid-luteal phases of the cycle. In corpora lutea from all stages of the menstrual cycle (excluding corpora albicantia), GnRH agonist binding was highly correlated with the levels of unoccupied and occupied LH receptors (P less than 0.001; n = 49 and n = 48 respectively) and with LDL receptors (P less than 0.002; n = 49). Binding of GnRH agonist was also correlated with PRL binding (P less than 0.05; n = 21) but not with FSH receptors (P greater than 0.4; n = 25). In addition, LDL binding was associated with PRL (P less than 0.005; n = 21) and FSH receptors (P less than 0.05; n = 25) and with endogenously bound LH (P less than 0.03; n = 48), but not with unoccupied LH receptors (P = 0.8; n = 49). Moreover, in corpora lutea from the mid-luteal phase, there was a strong association between GnRH agonist binding and LDL receptors (P less than 0.02; n = 23). The correlations between GnRH agonist binding and a number of important indices of luteal function suggest a physiological role for GnRH-like factors in the human corpus luteum.
在月经周期的黄体期，从52例行剖腹手术的女性中获取黄体。此外，从7例在卵泡晚期 - 排卵前期行卵巢切除术的女性中获取基质、卵泡膜和颗粒细胞制剂。在最佳条件下，测量了125I标记的促性腺激素释放激素（GnRH）激动剂[D - Ser(But)6]GnRH(1 - 9)-乙酰胺（布舍瑞林）以及人绒毛膜促性腺激素（hCG）、人促卵泡生成素（hFSH）、人催乳素（hPRL）和人低密度脂蛋白（hLDL）与组织匀浆的特异性结合。通过用酸 - 柠檬酸盐缓冲液洗脱，随后对释放的激素进行放射免疫测定来估计结合的LH/hCG。GnRH激动剂的结合虽有变化，但在黄体中期的黄体中最高，并且在妊娠黄体的四个中有三个也存在高结合。LH/hCG的结合随着黄体化显著增加，在黄体中期达到最高水平，然后显著下降。在整个黄体期，结合的LH对LH受体的占有率相对恒定（10.7 - 35.3%），但在妊娠早期的黄体中占有率增加到大于90%。hFSH的结合有变化，50个黄体中只有5个的结合大于10 pg/μg DNA。同样，hPRL结合变化明显，44个中只有6个的结合大于50 pg/μg DNA。LDL的结合在周期的黄体早期至中期最高。在月经周期所有阶段的黄体（不包括白体）中，GnRH激动剂结合与未占据和占据的LH受体水平高度相关（P < 0.001；分别为n = 49和n = 48）以及与LDL受体相关（P < 0.002；n = 49）。GnRH激动剂的结合也与PRL结合相关（P < 0.05；n = 21），但与FSH受体无关（P > 0.4；n = 25）。此外，LDL结合与PRL（P < 0.005；n = 21）和FSH受体（P < 0.05；n = 25）以及与内源性结合的LH（P < 0.03；n = 48）相关，但与未占据的LH受体无关（P = 0.8；n = 49）。此外，在黄体中期的黄体中，GnRH激动剂结合与LDL受体之间存在强关联（P < 0.02；n = 23）。GnRH激动剂结合与许多重要的黄体功能指标之间的相关性表明GnRH样因子在人黄体中具有生理作用。
